Molecular Partners Advances Radio-DARPin Programs with Strong Funding
Company Announcements

Molecular Partners Advances Radio-DARPin Programs with Strong Funding

Molecular Partners (MOLN) has released an update.

Molecular Partners, a clinical-stage biotech company, has announced significant advancements in its Radio-DARPin therapeutic programs, including preparations for clinical trials of its MP0712 candidate in 2025. The company has strengthened its partnership with Orano Med to co-develop four 212Pb-based candidates and raised approximately USD 20 million in a recent offering to support its R&D initiatives. With a robust cash position of CHF 158 million, Molecular Partners is well-funded into 2027, indicating strong financial health and growth potential.

For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMolecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M
TipRanks Auto-Generated NewsdeskMolecular Partners to Boost Finances with Share Sale
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App